David Efraim Rosen insider trades: Collegium Pharmaceutical (COLL) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where David reports to the SEC
Open-market buys and sales
22 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Aug 13, 2025 | COLL | ↓ Sell | 25,000 | $37.85 | $946K | Indirect | Aug 15, 2025 (2d) |
| Aug 8, 2025 | HRTX | ↑ Buy | 2,387,225 | $1.50 | $3.6M | Indirect | Aug 12, 2025 (4d) |
| Jun 27, 2025 | TLN | ↓ Sell | 344,187 | $294.31 | $101.3M | Indirect | Jun 27, 2025 (0d) |
| Jun 25, 2025 | TLN | ↓ Sell | 44,343 | $288.55 | $12.8M | Indirect | Jun 27, 2025 (2d) |
| Dec 13, 2024 | TLN | ↓ Sell | 4,893,507 | $204.35 | $1000.0M | Indirect | Dec 16, 2024 (3d) |
| Dec 30, 2022 | TXMD | ↓ Sell | 29,000 | $1333.00 | $38.7M | Indirect | Jan 3, 2023 (4d) |
| Dec 9, 2022 | TXMD | ↑ Buy | 14,825 | $6.09 | $90K | Indirect | Dec 12, 2022 (3d) |
| Dec 8, 2022 | TXMD | ↑ Buy | 300 | $5.83 | $2K | Indirect | Dec 9, 2022 (1d) |
| Dec 7, 2022 | TXMD | ↑ Buy | 20,113 | $5.66 | $114K | Indirect | Dec 9, 2022 (2d) |
| Oct 28, 2022 | TXMD | ↑ Buy | 7,000 | $1000.00 | $7.0M | Indirect | Oct 31, 2022 (3d) |
| Sep 30, 2022 | TXMD | ↑ Buy | 7,000 | $1000.00 | $7.0M | Indirect | Oct 3, 2022 (3d) |
| Aug 11, 2022 | RDUS | ↑ Buy | 1,678,954 | $10.07 | $16.9M | Indirect | Aug 12, 2022 (1d) |
| Aug 10, 2022 | RDUS | ↑ Buy | 4,012 | $10.07 | $40K | Indirect | Aug 11, 2022 (1d) |
| Jul 29, 2022 | TXMD | ↑ Buy | 15,000 | $822.21 | $12.3M | Indirect | Aug 1, 2022 (3d) |
| Jul 29, 2022 | TXMD | ↑ Buy | 565,000 | $4.72 | $2.7M | Indirect | Aug 1, 2022 (3d) |
| Jul 18, 2022 | TXMD | ↑ Buy | 17,688 | $6.03 | $107K | Indirect | Jul 19, 2022 (1d) |
| Jul 15, 2022 | TXMD | ↑ Buy | 64,892 | $5.56 | $361K | Indirect | Jul 19, 2022 (4d) |
| Dec 16, 2021 | RDUS | ↑ Buy | 146,685 | $7.07 | $1.0M | Indirect | Dec 16, 2021 (0d) |
| Dec 15, 2021 | RDUS | ↑ Buy | 274,847 | $6.78 | $1.9M | Indirect | Dec 15, 2021 (0d) |
| Dec 13, 2021 | RDUS | ↑ Buy | 187,391 | $7.08 | $1.3M | Indirect | Dec 15, 2021 (2d) |
| Dec 10, 2021 | RDUS | ↑ Buy | 1,032,815 | $7.28 | $7.5M | Indirect | Dec 10, 2021 (0d) |
| Dec 8, 2021 | RDUS | ↑ Buy | 560,691 | $8.02 | $4.5M | Indirect | Dec 10, 2021 (2d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other COLL insiders
Open-market trades in the last 12 months
About David Efraim Rosen's insider trades
David Efraim Rosen is a 10% owner of Collegium Pharmaceutical (COLL). Since Dec 8, 2021, David has reported 17 open-market purchases worth $66.4M and 5 sales worth $1.15B on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include other transactions (3 filings), grants and awards (3 filings), conversions (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every COLL insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.